STOCK TITAN
  1. Home
  2. News
  3. WVE

Wave Life Sciences Ltd. - WVE STOCK NEWS

IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
clinical trial
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
conferences earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Present at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
conferences earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
clinical trial
Stock WVE logo
Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#3558 Ranked by Market Cap
#1217 Ranked by Stock Gains
N/A Ranked by Dividends

WVE Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Singapore
7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.